Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions containing magnolol, honokiol and nonsteroidal antiinflammatory drug, and applications thereof

A non-steroidal anti-inflammatory drug and honokiol technology, applied in the field of new drug compounds, can solve the problems of incomplete absorption, limited application, low activity, etc., and achieve the advantages of reducing side effects, good anti-inflammatory effect, and improving anti-inflammatory effect. Effect

Inactive Publication Date: 2017-04-12
GUANGDONG UNIV OF TECH
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, further studies have found that the activity of magnolol and honokiol in the body is low, and the absorption is not complete, which greatly limits its application. Currently, magnolol and honokiol are used in combination with other anti-inflammatory activities. The natural products are mainly concentrated in CN 101516364A; CN 101945651A; CN 101384265A

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions containing magnolol, honokiol and nonsteroidal antiinflammatory drug, and applications thereof
  • Compositions containing magnolol, honokiol and nonsteroidal antiinflammatory drug, and applications thereof
  • Compositions containing magnolol, honokiol and nonsteroidal antiinflammatory drug, and applications thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Example 1: Effect of Composition on Mouse Inflammation Model

[0022] 1.1 Experimental materials

[0023] SPF grade KM mice, female, weighing about 18-22 g, were provided by the Experimental Animal Center of Sun Yat-sen University (certificate number: SCXK / 20130002). Hole punch (diameter 6mm), purchased by yourself.

[0024] 1.2 Experimental method

[0025] 27 female KM mice were randomly divided into blank control group, TPA-induced inflammation group, positive control drug curcumin group, and composition group, a total of 9 groups with 3 mice in each group. After 10 minutes, the same amount of TPA 15 μL was applied to the front and back of the left and right ears of the mice in each group to cause inflammation. After 6 hours, the mice were killed by dislocation of the cervical spine, and the left and right ears were punched with a 6 mm diameter punch. The discs at the same site were weighed on an analytical balance, and the difference in weight between the left and...

Embodiment 2

[0050] Example 2: Effect of Composition on Mouse Inflammation Model

[0051] 2.1 Effects on TPA-induced ear swelling in mice

[0052] In order to investigate the influence of the magnolol compound concentration on the mouse auricle swelling inhibitory effect, different drugs were applied to the mouse ears according to the above-mentioned animal model. The effects of different magnolol compositions on the swelling inhibition of the mouse auricle were measured by recording the weight of the mouse auricle, and acetone was used as a control.

[0053] The influence of table 6 composition on TPA-induced mouse auricle swelling

[0054]

[0055]

[0056] Compared with the negative control group, *: P<0.05.

[0057] As shown in Table 6, the inhibition rate of the parent drug magnolol alone was 54.7%, and that of naproxen was 66.7%. Among them, the inhibition rate of 16 compositions is greater than 66.7%. Moreover, among these compounds, 10 compositions have obvious inhibitory...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Weightaaaaaaaaaa
Diameteraaaaaaaaaa
Login to View More

Abstract

The present invention discloses synergistic effects and applications of a series of compositions comprising magnolol, honokiol and a nonsteroidal antiinflammatory drug, wherein the chemical formulas of magnolol and honokiol are represented by a formula (I), and the chemical formula of the nonsteroidal antiinflammatory drug is represented by a formula (II). The invention further relates to applications of the compositions in anti-inflammatory drugs, drugs for skin, cosmetic protection, and other fields. The formulas I and II are defined in the specification.

Description

technical field [0001] The invention relates to the technical field of new drug compounds, in particular to magnolol and the synergistic anti-inflammatory effect of honokiol and non-steroidal anti-inflammatory drug composition and application thereof. [0002] technical background [0003] Nonsteroidal anti-inflammatory drugs (NSAIDs) are a class of drugs with antipyretic, analgesic, and anti-inflammatory effects. Treatment of diseases and soft tissue and sports injuries. However, long-term high-dose oral NSAIDs will bring a series of side effects to patients, such as gastrointestinal bleeding, liver and kidney damage, and cardiovascular damage. The skin smear preparations have many advantages such as avoiding the liver first-pass effect and reducing gastrointestinal bleeding and other side effects, which make NSAIDs skin smear preparations have a wide application prospect. At present, the combined use of naproxen with other biologically active drugs is mainly concentrated ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/196A61K31/05A61K31/603A61K31/192A61P29/00A61P17/00A61K8/36A61K8/33A61K8/44A61K8/365A61Q19/00
Inventor 杜志云月圆刘文锋张焜郑希董宇琴张秋炎卢宇靖王华倩郑俊霞董长治陈惠雄何燕
Owner GUANGDONG UNIV OF TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com